Ketamine Challenge Study With JNJ-40411813

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

The objective of this study is to investigate whether JNJ-40411813 versus placebo reduces psychosis-like symptoms, induced by infusion of a low dose of ketamine. Effects of JNJ-40411813 on ketamine-induced symptoms will be evaluated about 3 hours after a single oral dose when the concentration of JNJ-40411813 in the blood is at its maximum and up to 24 hours after dose administration to assess the duration of a potential JNJ-40411813 effect.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Treatments: Ketamine

Criteria

Inclusion Criteria:

• Body mass index (BMI) between 18 and 30 kg/m2

• Nonsmokers

• Healthy on the basis of a psychiatric examination according to the MINI screen

• Healthy on the basis of clinical laboratory tests performed at screening

• Healthy on the basis of physical examination, vital signs (including standing blood pressure and heart rate) or 12 lead ECG at Screening

Exclusion Criteria:

• Having a contra-indication for the use of ketamine

• Significant history of or current psychiatric or neurological illness

• Positive urine screen for drugs of abuse at Screening or admission

• Positive alcohol breath test at Screening or admission

• History of alcohol or drug abuse